BioWorld
-
Sanofi's sutimlimab delivers benefit for CAD patients in phase III study
-
With reduced toxicity, can HSCT make it to Hall of Fame?
-
In all Candor, Darzalex has positive data
-
Summit raising $50M, gaining majority stakeholder and dropping AIM listing
-
Equillium tell: Fast track for itolizumab shows FDA faith that CD6 targeter could hit mark in lupus nephritis
-
Australia’s R&D tax incentive threatened yet again
-
Immunos raises $15M for multitasking immune-activating agents
-
Lyndra drug delivery tech for a once-monthly birth control pill tested in animals
-
Bruton soup’s on: Merck paying $2.7B for Arqule, Aptose bubbles as Lilly data cool at ASH
BioWorld MedTech
-
Imperative Care gets $85M to market aspiration-based devices to treat a broader range of stroke
-
Prerevenue med-tech Venus raises $308M on HKEX
-
DC district court hands FDA a product jurisdiction loss in barium sulfate suit
-
Synaptive Medical announces close of $25M preferred share financing to expand global footprint
-
With reduced toxicity, can HSCT make it to Hall of Fame?
-
Bioworld MedTech’s Oncology Extra for Dec. 10, 2019
-
Lantheus expands microbubble, cancer applications with Carthera collaboration
-
Novel technologies may drive tighter controls for ethylene oxide sterilization
-
Advanced Oncotherapy readies first linear proton beam accelerator system for debut
BioWorld Asia
-
Luye Pharma bids to acquires Boan in $205M deal to compete in biologics
-
Emphasizing synergy and efficiency, EOC Pharma raises $71M series C to fight breast, gastric cancers
-
New PCa treatment strategy may overcome resistance
-
With another $26M, Japan’s Heartseed aims to advance iPSC-derived regenerative medicine for heart failure
-
Rapt licenses FLX-475 to Hanmi in deal worth up to $118M
-
China’s Clover completes $43M series B
-
South Korea’s Avixgen secures ₩10.6 billion in pre-IPO investment
-
Alteogen licenses ALT-B4 to a top 10 global pharma in potential $1B+ deal
-
Celltrion’s Remsima SC wins marketing approval in EU
